Explore more
News
Pfizer Strikes Deal With China's 3SBio
Digest more
14hon MSN
Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains. The Investment Committee debate the ...
Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...
Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.
Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...
Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...
The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.
The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...
Pfizer share price gained 13% in the intraday trades on Tuesday post Q4 Results, dividend announcement and despite stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback